Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
09:04pm, Tuesday, 12'th Nov 2019
SAN DIEGO, Nov. 12, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline
03:31pm, Tuesday, 05'th Nov 2019
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We're Not Very Worried About Crinetics Pharmaceuticals's (NASDAQ:CRNX) Cash Burn Rate
03:31pm, Monday, 28'th Oct 2019
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
11:30am, Wednesday, 25'th Sep 2019
SAN DIEGO, Sept. 25, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?
12:40pm, Thursday, 12'th Sep 2019
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
08:05pm, Tuesday, 03'rd Sep 2019
SAN DIEGO, Sept. 03, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
10:15pm, Tuesday, 13'th Aug 2019
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08:14pm, Tuesday, 13'th Aug 2019
SAN DIEGO, Aug. 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
If You Had Bought Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today
06:35pm, Tuesday, 30'th Jul 2019
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
11:30am, Monday, 29'th Jul 2019
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endoc
Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors
01:05pm, Tuesday, 16'th Jul 2019
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocr
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
11:30am, Tuesday, 19'th Mar 2019
SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of n
